Literature DB >> 26510649

Cirrhosis-related hyponatremia and the role of tolvaptan.

Motoh Iwasa1, Tomoaki Ishihara2, Hiroshi Hasegawa1, Yoshiyuki Takei1.   

Abstract

Entities:  

Year:  2015        PMID： 26510649     DOI： 10.1111/hepr.12471

Source DB:  PubMed          Journal:  Hepatol Res        ISSN： 1386-6346            Impact factor:   4.288


× No keyword cloud information.
  2 in total

1.  The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.

Authors:  Tomomi Kogiso; Mutsuki Kobayashi; Kuniko Yamamoto; Yuichi Ikarashi; Kazuhisa Kodama; Makiko Taniai; Nobuyuki Torii; Etsuko Hashimoto; Katsutoshi Tokushige
Journal:  Intern Med       Date:  2017-09-25       Impact factor: 1.271

2.  Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model.

Authors:  Norikazu Tanabe; Taro Takami; Koichi Fujisawa; Toshihiko Matsumoto; Naoki Yamamoto; Isao Sakaida
Journal:  J Clin Biochem Nutr       Date:  2017-05-16       Impact factor: 3.114
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.